Bone marrow-derived progenitor cells for myocardial infarction

In previous clinical trials, it was found that treatment of myocardial infarction (MI) patients by intracoronary administration of 12.6±2.2×10^6 a cell suspension enriched with CD133+ cells is feasible but was associated with increased incidence of coronary events. Nevertheless, it seemed to be associated with improved left ventricular performance, which paralleled increased myocardial perfusion and viability. In patients treated <7 days following MI, there was accelerated luminal loss and reduced conductance of the infarct-related artery.